PB1762 A PHASE III, RANDOMIZED, DOUBLE‐BLIND STUDY OF INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY PLUS MIDOSTAURIN (PKC412) OR PLACEBO IN NEWLY DIAGNOSED PATIENTS WITH FLT3 MUTATION NEGATIVE AML | Publicación